Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) released its earnings results on Wednesday. The biopharmaceutical company reported $0.27 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.25 by $0.02, Bloomberg Earnings reports. Sucampo Pharmaceuticals had a negative net margin of 61.99% and a positive return on equity of 56.58%. The firm had revenue of $61.27 million during the quarter, compared to analyst estimates of $58.05 million. During the same period last year, the business earned $0.30 earnings per share. The business’s revenue was up 5.9% on a year-over-year basis. Sucampo Pharmaceuticals updated its FY17 guidance to $1.10-1.15 EPS.
In other news, insider Jason Patrick Meyenburg bought 4,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 6th. The stock was bought at an average price of $12.13 per share, with a total value of $48,520.00. Following the completion of the transaction, the insider now directly owns 30,228 shares of the company’s stock, valued at approximately $366,665.64. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jones W. Bryan bought 4,700 shares of the firm’s stock in a transaction that occurred on Friday, August 4th. The shares were purchased at an average cost of $10.60 per share, with a total value of $49,820.00. Following the transaction, the insider now directly owns 4,700 shares of the company’s stock, valued at $49,820. The disclosure for this purchase can be found here. 4.13% of the stock is currently owned by corporate insiders.
Several research firms have recently issued reports on SCMP. BidaskClub lowered shares of Sucampo Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, August 5th. Mizuho lowered shares of Sucampo Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their target price for the company from $14.00 to $12.00 in a report on Tuesday, October 3rd. UBS AG lowered their target price on shares of Sucampo Pharmaceuticals from $19.00 to $15.00 and set a “buy” rating for the company in a report on Thursday, October 12th. Zacks Investment Research upgraded shares of Sucampo Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, October 3rd. Finally, Maxim Group reiterated a “buy” rating and set a $23.00 target price (up from $21.00) on shares of Sucampo Pharmaceuticals in a report on Tuesday, August 8th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $16.50.
About Sucampo Pharmaceuticals
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
What are top analysts saying about Sucampo Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sucampo Pharmaceuticals Inc. and related companies.